KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer - VJOncology Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy...

⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:

➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...

🎥 buff.ly/0R25Yjb

#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc

BS
Interested in the latest developments in #BreastCancer? Check out the most recent articles from #ESMOBreast25 in the #ESMODailyReporter and stay up-to-date with the cutting-edge developments in #oncology

🔗 buff.ly/ltSvODu

Living well with breast cancer, and the latest breakthroughs From targeted therapies and artificial intelligence to the unique challenges faced by younger women, experts at ESMO Breast Cancer 2025 say treatments are improving, but care must go further.

🩺 Cure may still be elusive—but long-term control is real.
At #ESMOBreast25, experts shared what’s changing in breast cancer care:
🧬 Immunotherapy
🧪 Liquid biopsy
🧠 Digital survivorship support
Read our latest: medicalnewsinsider.substack.com/p/living-wel...
#BreastCancer #CancerSurvivorship

#ESMOBreast25: Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted #AntibodyDrugConjugate in women receiving at least one prior topoisomerase-1 #ADC.

Read the full article in the #ESMODailyReporter

🔗 buff.ly/nHI7BbH

postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer @myesmo.bsky.social #ESMOBreast25 #bcsm #oncology

www.onclive.com/view/postmon...

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer - OncoDaily DESTINY-Breast06 trial shows T-DXd improves PFS over chemo in HR+/HER2-low mBC after endocrine therapy. Latest results from ESMO Breast 2025.

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow mBC
@myesmo.bsky.social @eliasegui.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DESTINY-Breast06 #ESMOBreast25 #BreastCancer

HYPART Trial: Testing 1-Week vs. 2-Week Radiotherapy for High-Risk Breast Cancer at ESMO Breast 2025 - OncoDaily HYPART Trial: Testing 1-Week vs. 2-Week Radiotherapy for High-Risk Breast Cancer at ESMO Breast 2025 / cancer, ESMO, ESMO Breast 2025, Oncology, radiation

HYPART Trial: Testing 1-Week vs. 2-Week Radiotherapy for High-Risk Breast Cancer at ESMO Breast 2025
@myesmo.bsky.social

oncodaily.com/blog/hypart-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #HYPART #ESMOBreast25

DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2 Positive Breast Cancer - OncoDaily Dual checkpoint blockade with tremelimumab + durvalumab shows promise in HER2-positive advanced breast cancer with trastuzumab resistance in the DIAmOND trial at ESMO 2025.

DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2+ Breast Cancer
@myesmo.bsky.social @loisher.bsky.social

oncodaily.com/science/diam...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DIAmOND #ESMOBreast25

Do clinicians and patients see the same picture?

In adjuvant BC therapy trials, agreement on side effects is weak. Patient-reported outcomes (#PROs) show symptoms that doctors often don't see.

Both views are vital for patient-centred care.

#ESMOBreast25

In her Keynote Lecture, Ann Partridge discusses recent progress in the treatment of young women with #BreastCancer, considering some of the unique needs and challenges, and key initiatives such as the BCY session at #ESMOBreast25

🔗 bit.ly/ESMO2025

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.

T-DM1 Plus Palbociclib Displays Activity in HER2+ Metastatic Breast Cancer @gwcancercenter.bsky.social @myesmo.bsky.social #ESMOBreast25 #bcsm #oncology
www.onclive.com/view/t-dm1-p...

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer - OncoDaily DESTINY-Breast06 trial shows T-DXd improves PFS over chemo in HR+/HER2-low mBC after endocrine therapy. Latest results from ESMO Breast 2025.

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer
@myesmo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DESTINY-Breast06 #ESMOBreast25 #BreastCancer #MBC

EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.

EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC @gustaveroussy.fr @myesmo.bsky.social #ESMOBreast25 #bcsm #oncology www.onclive.com/view/el1ssar...

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer @myesmo.bsky.social #ESMOBreast25 #bcsm #oncology

www.onclive.com/view/durvalu...

PostMONARCH: Abemaciclib Combo Effective After CDK4/6i Failure | Docwire News Abemaciclib plus fulvestrant showed benefit across biomarkers after CDK4/6i failure in advanced HR+/HER2- breast cancer.

New postMONARCH data show abemaciclib + fulvestrant improves outcomes in HR+/HER2– mBC after CDK4/6i failure—benefit seen across key biomarker subgroups. docwirenews.com/post/postmon... #ESMOBreast25 #bcsm
@myesmo.bsky.social

Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.

Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer
@myesmo.bsky.social #ESMOBreast25 #bcsm #oncology www.onclive.com/view/neoadju...

Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer
#BreastCancer @myesmo.bsky.social #ESMOBreast25
www.onclive.com/view/iza-bre...

In her Keynote Lecture, Ann Partridge discusses recent progress in the treatment of young women with #BreastCancer, considering some of the unique needs and challenges, and key initiatives such as the BCY session at #ESMOBreast25 #ESMODailyReporter

🔗 ow.ly/aiLl50VTYbX

#ESMOBreast25
👏👏👏 @cancerresearch-ucc.bsky.social Academic Intern Dr Clara Steele

High levels of interest & engagement among ☘️ breast cancer patients for Secondary Risk Reduction Services

Time to integrate this into Routine Survivorship Care @roinnslainte.bsky.social @cancertrialsie.bsky.social

On 15 May, CPE joined #ESMOBreast25 in Munich.

Key survey findings on ESR1 and liquid biopsy in mBC were shared, revealing major gaps in patient awareness.

CPE continues to push for better education and access to personalised care.

🔗 Learn more: lnkd.in/dXC5VxyF

Key takeaways from #esmobreast25

#breastcancer #oncology #munich

The @OncoAlert 🚨 @VJOncology JOURNAL CLUB
Today we present @E_de_Azambuja 🇧🇪of @JulesBordet who talks to us about the Final Analysis of the APHINITY trial just Presented at #ESMOBreast25
youtu.be/ydcXe_faQH0

A sub analysis was just published out on European Journal of Cancer: